AB SCIEX announces business expansion in Brazil AB SCIEX.

AB SCIEX excels by listening to and understanding the ever-evolving requirements of its customers to develop reliable, sensitive and intuitive LC/MS/MS solutions that continue steadily to redefine what is achievable in routine and complex analysis. Supporting these workflow solutions are AB SCIEX’s world-class support and support.. AB SCIEX announces business expansion in Brazil AB SCIEX, a worldwide leader in life science analytical technology, today announced its growth of commercial operations in Brazil to support the Brazilian scientific community’s increasing usage of mass spectrometry for food safety testing, environmental analysis, academic research, drug development, forensic toxicology and clinical study.3SBio's proven features in biologicals, combined with Zhejiang Wansheng's expertise in small molecule manufacturing, will provide the enlarged group with a flexible system for addressing the unmet medical needs of individuals and their healthcare professionals. Zhejiang Wansheng's current item portfolio includes six antidiabetic and hypertension products that are commonly utilized by chronic kidney disease patients, that may expand our products giving in the dialysis marketplace in addition to our current nephrology portfolio. The acquisition also expands our portfolio of oncology medications as Zhejiang Wansheng has six approved oncology products, commented Dr. Lou Jing, CEO and Chairman of 3SBio. The acquisition will further solidify 3SBio's leading position in nephrology and oncology since it also offers a platform for the business to proceed with the clinical advancement of over 12 small-molecule pipeline candidates in our primary therapeutic areas using internal facilities and expertise, including HIF-PH inhibitor for anemia; cinacalcet hydrochloride for hyperparathyroidism; sevelamer carbonate for hyperphosphatemia; Colestilan for hypercholesteremia and hyperphosphatemia; DJ5 for autosomal dominant polycystic kidney disease ; PEG-Irinotecanfor solid tumors; nadroparin calcium for bloodstream clotting and thrombosis; and fondaparinux sodium for prophylaxis of deep vein thrombosis.